To evaluate the effectiveness of vinorelbine (NVB) in patients with non-small cell lung
cancer (NSCLC), a late Phase II study was conducted. A total of 80 patients with Stage III or …

OBJECTIVE: To review the chemistry, pharmacology, pharmacokinetics, clinical activity,
adverse effects, and dosage and administration guidelines for vinorelbine in the treatment of …

Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food
and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The …

Vinorelbine is a new semisynthetic vinca alkaloid. Data from in vitro and in vivo preclinical
studies suggest that vinorelbine is active in both small cell lung cancer (SCLC) and non …

Vinorelbine (navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre
Medicament, Paris, France), a novel semisynthetic vinca alkaloid, is the first drug approved …

The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and
dosage and administration of vinorelbine are reviewed. Vinorelbine is a semisynthetic vinca …

Purpose A randomized phase II trial of oral vs. intravenous (iv) vinorelbine was designed to
determine the efficacy and safety of oral vinorelbine with an intrapatient dose escalation in …

Vinorelbine (Navelbine') is a new, semisynthetic 5'Nor-vinca-alkaloid, modified on the
catharantine ring, developed by Pierre Fabre Medicament. Vinorelbine is as potent as the …

Phase II studies have demonstrated that vinorelbine (Navelbine; Burroughs Wellcome Co,
Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) alone or in …

Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC),
both as a single agent and in combination chemotherapy. Recently, an oral form of this …